In conversation with Nina Bauer: CAR-T milestones, navigating investment landscapes, and the three Ps of CGT

Meet the Cell & Gene Therapy Insights Editorial BoardWith 17 years of experience across academia, start-ups, pharma, and investment, Dr Nina G Bauer brings a unique, cross-sector perspective to the evolution of CGTs. As an Editorial Advisory Board member for Cell & Gene Therapy Insights, she reflects on the landmark approval of Kymriah, the rapid progress in in vivo CAR-T and non-viral delivery technologies, and the strategic and economic considerations shaping CGT’s path toward accessibility and long-term sustainability.